Data as of .
BIOY vs FINY: which paid, and which earned it?
Over the window both share BIOY paid 20.6% of its price in cash against FINY’s 7.7%, though FINY returned more with it reinvested.
What they hold in common
By the books each fund has filed, BIOY and FINY hold 100% of their money in the same securities at the same weight.
| Holding | BIOY | FINY |
|---|---|---|
| Treasury Bill | 100.00% | 100.00% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
Performance, window by window
| Window | Total return | Cash paid | Against the benchmark | |||
|---|---|---|---|---|---|---|
| BIOY | FINY | BIOY | FINY | BIOY | FINY | |
| 3 months | +2.5% | +5.0% | 14.1% | 4.2% | −9.0 pts | +0.4 pts |
| Since launch | +2.0% | +9.2% | 20.6% | 7.7% | −15.3 pts | +0.6 pts |
| BIOY GraniteShares YieldBOOST Biotech ETF Synthetic covered call on XBI, paying weekly | FINY GraniteShares YieldBOOST Financials ETF Synthetic covered call on XLF, paying weekly | |
|---|---|---|
| Issuer | GraniteShares | GraniteShares |
| Strategy | synthetic covered call | synthetic covered call |
| Benchmark | Biotech (XBI), used as the proxy | Financials sector (XLF) |
| Pays | weekly | weekly |
| Payout rate, annualized | 60.0% | 11.2% |
| Expense ratio | 1.07% | 1.07% |
| Cash paid, 1 year | 20.6% (since launch on May 5, 2026) | 7.7% (since launch on May 5, 2026) |
| Price change, 1 year | −19.0% | +1.2% |
| Total return, 1 year | +2.0% (since launch on May 5, 2026) | +9.2% (since launch on May 5, 2026) |
| Benchmark return, 1 year | +17.3% | +8.7% |
| Ahead or behind | −15.3 pts | +0.6 pts |
| Return of capital, latest estimate | 96% | 96% |
| Age | 136 days | 136 days |
| Net assets | $1m | $760,476 |
BIOY in plain words
Over the period since launch on May 5, 2026 to Sep 18, 2026, BIOY paid 20.6% of its starting value in cash distributions while its price fell 19.0%. With every distribution reinvested, the fund returned +2.0%. Biotech (XBI), used as the proxy returned +17.3% over the same days, so a holder was behind by 15.3 pts. At its price on Sep 18, 2026 the latest distribution annualizes to 60.0%, paid weekly. GraniteShares estimates that 96% of the distribution paid Aug 25, 2026 was a return of capital (19a-1 notice, estimated, a tax characterization rather than a measure of erosion).
FINY in plain words
Over the period since launch on May 5, 2026 to Sep 18, 2026, FINY paid 7.7% of its starting value in cash distributions while its price rose 1.2%. With every distribution reinvested, the fund returned +9.2%. Financials sector (XLF) returned +8.7% over the same days, so a holder was ahead by 0.6 pts. At its price on Sep 18, 2026 the latest distribution annualizes to 11.2%, paid weekly. GraniteShares estimates that 96% of the distribution paid Jul 7, 2026 was a return of capital (19a-1 notice, estimated, a tax characterization rather than a measure of erosion).
Questions people ask
- Which paid more, BIOY or FINY?
- Over the year to Sep 18, 2026, BIOY paid 20.6% of its starting price in cash and FINY paid 7.7%, so BIOY paid more. Cash paid is not the same as money made: the price change matters too.
- Which returned more once distributions are counted, BIOY or FINY?
- With every distribution reinvested, BIOY returned +2.0% and FINY returned +9.2% over the year to Sep 18, 2026, so FINY returned more.
- Which is cheaper, BIOY or FINY?
- BIOY charges 1.07% a year and FINY charges 1.07%, so BIOY is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, BIOY against FINY, data as of Sep 18, 2026. https://etfiq.com/compare/income/bioy-vs-finy Free to use with attribution; the underlying files are at Open data.